TABLE 1.

Fluconazole susceptibilities of 426 isolates of Candida spp. as determined by the VITEK 2 yeast susceptibility test and by CLSI BMD methods^a

Species	No. tested	Test methodb	MIC (μg/ml)c			EA (%)d
			Range	50%	90%
C. albicans	198	VITEK 2	≤1-≥64	≤1	≤1
		BMD-24	≤0.12-≥128	0.25	0.5	97.0
		BMD-48	≤0.12-≥128	0.25	0.5	96.5
C. dubliniensis	8	VITEK 2	≤1-32	≤1
		BMD-24	≤0.12-16	≤0.12		100.0
		BMD-48	≤0.12-16	0.25		100.0
C. glabrata	83	VITEK 2	≤1-≥64	8	≥64
		BMD-24	0.5-≥128	4	64	98.8
		BMD-48	0.5-≥128	16	≥128	96.4
C. guilliermondii	3	VITEK 2	≤1-4	2
		BMD-24	1-4	4		100.0
		BMD-48	2-4	4		100.0
C. krusei	51	VITEK 2	≤1-≥64	16	32
		BMD-24	≤1-≥128	16	32	100.0
		BMD-48	≤1-≥128	64	≥128	68.6
C. lusitaniae	9	VITEK 2	≤1-2	1
		BMD-24	≤0.12-1	0.5		100.0
		BMD-48	≤0.12-2	0.5		100.0
C. norvegensis	1	VITEK 2	8
		BMD-24	16			100.0
		BMD-48	16			100.0
C. parapsilosis	43	VITEK 2	≤1-≥64	≤1	2
		BMD-24	0.25-4	0.5	1	95.3
		BMD-48	0.5-4	1	2	97.7
C. pelliculosa	2	VITEK 2	2-4	2
		BMD-24	2-4	2		100.0
		BMD-48	4	4		100.0
C. tropicalis	28	VITEK 2	≤1-8	≤1	≤1
		BMD-24	≤0.12-8	0.25	1	100.0
		BMD-48	0.25-16	0.5	4	100.0
All Candida spp.	426	VITEK 2	≤1-≥64	≤1	16
		BMD-24	≤0.12-≥128	0.5	16	97.9
		BMD-48	≤0.12-≥128	0.5	64	93.7

^aIsolates included both clinical (n = 346) and challenge (n = 80) sets.

^bBMD-24 and BMD-48, BMD performed at 24 h and 48 h of incubation, respectively.

^c50% and 90%, MICs encompassing 50% and 90% of isolates tested, respectively.

^d% EA is the EA (±2 log₂ dilutions) between VITEK 2 and BMD MICs.